Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia
Saudi Medical Journal · 08.08.2026 · 47 (9) · 1516-1523
DOI: 10.15537/1658-3175.8842 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Saudi Medical Journal, online erschienen am 08.08.2026. Verfasst von Mansour A Tobaiqy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the perceptions, experiences, and safety concerns of patients regarding the glucagon-like peptide-1 (GLP-1) receptor agonists. Obesity is a significant public health issue. The newer anti-obesity medications: GLP-1 receptor agonists, with an increase in therapeutic options. However, little is known about the perceived benefits, safety, cost, and accessibility.
Methods
Cross-sectional survey included adults who previously used at least 1 anti-obesity medication and conducted in 3 general hospitals in Jeddah, Kingdom of Saudi Arabia (KSA) during June 2025 to February 2026. The questionnaire was created after reviewing the current evidence and validated the contents. It included questions on demographic and clinical information, medication use patterns, perceptions, and safety experiences. Data were analyzed using descriptive statistics.
Results
A total of 365 participants (median age: 41 years; 55.3% female) included, with a median body mass index (BMI) of 29.59 kg/m2 and 48.6% were obese. Current medication use was 63.3%, associated with diabetes, hypertension, hypercholesterolemia, family obesity history, and higher BMI. Duration of use was statistically significant (p = 0.001), with tirzepatide used for longer durations and semaglutide for shorter durations. Perceived safety was significantly associated with the duration of use (p = 0.001). Despite adverse effects reporting, many questioned effectiveness, information adequacy and safety.
Conclusion
Substantial gaps in perceived effectiveness, safety confidence, affordability, and therapy continuity of GLP-1 receptor. This highlights need for structured education, improved access, and system interventions to improve anti-obesity pharmacotherapy adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
- Departmant of Family and Community Medicine, College of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
- College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
ORCID-Profile: Mansour A Tobaiqy, Sulafa T Alqutub
Zitieren
APA
Tobaiqy, M. A., Alqutub, S. T., Alzahrani, M. A., Alazwari, R. H., & Asiri, F. A. (2026). Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia. Saudi Medical Journal, 47(9), 1516-1523. https://doi.org/10.15537/1658-3175.8842
Vancouver
Tobaiqy MA, Alqutub ST, Alzahrani MA, Alazwari RH, Asiri FA. Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia. Saudi Medical Journal. 2026;47(9):1516-1523. doi:10.15537/1658-3175.8842
BibTeX
@article{Tobaiqy2026,
author = {Tobaiqy, Mansour A and Alqutub, Sulafa T and Alzahrani, Mohammed A and Alazwari, Renad H and Asiri, Faisal A},
title = {Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia},
journal = {Saudi Medical Journal},
year = {2026},
volume = {47},
number = {9},
pages = {1516--1523},
doi = {10.15537/1658-3175.8842}
}
EUVIMED